ImmunoGen, Inc.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase…

Biotechnology

US, Waltham [HQ]

Overview
Fin. Reports
Financials
Leadership & Strategy
Government, Law & Regulation
Employees
More

Financials

Earnings Call Transcripts

Earnings Call · Transcripts · Speakers

This analysis tool shows transcript versions of the official earnings calls hosted by ImmunoGen, Inc.

Could not find a transcript

Transcripts

Could not find a transcript

Peers Transcripts

Peers Analysis

Sorry! None of IMGN's peers has listed transcripts.

SEC Reader

The document search tool might be interesting as well.
Give it a try, to quickly access SEC Filings-

10-K · 10-Q · DEF 14A · S-4

Upcoming Transcript Tools

Full Text Search - Across All Transcripts
Detail Speaker Profiles
Non-US Transcripts